Northern Trust Corp Aravive, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.11 - $1.76 $14 - $232	132 Added 0.18%	74,696 $9,000
Q2 2023 Aug 11, 2023	BUY	$1.25 - $1.92 $11,048 - $16,970	8,839 Added 13.45%	74,564 $93,000
Q1 2023 May 15, 2023	SELL	$1.29 - $2.46 $11,357 - $21,657	-8,804 Reduced 11.81%	65,725 $131,000
Q4 2022 Feb 13, 2023	BUY	$1.2 - $1.83 $43,318 - $66,061	36,099 Added 93.93%	74,529 $98,000
Q3 2022 Nov 14, 2022	BUY	$0.61 - $1.03 $3,389 - $5,722	5,556 Added 16.9%	38,430 $31,000
Q1 2022 May 13, 2022	SELL	$1.85 - $2.75 $965 - $1,435	-522 Reduced 1.56%	32,874 $63,000
Q4 2021 Feb 08, 2022	SELL	$2.19 - $4.07 $628 - $1,168	-287 Reduced 0.85%	33,396 $73,000
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $9,314 - $14,720	-2,538 Reduced 7.01%	33,683 $125,000
Q2 2021 Aug 13, 2021	SELL	$4.65 - $6.42 $494,085 - $682,157	-106,255 Reduced 74.58%	36,221 $217,000
Q1 2021 May 12, 2021	SELL	$5.11 - $9.24 $77,661 - $140,429	-15,198 Reduced 9.64%	142,476 $939,000
Q4 2020 Feb 11, 2021	SELL	$4.36 - $6.51 $16,062 - $23,982	-3,684 Reduced 2.28%	157,674 $889,000
Q3 2020 Nov 16, 2020	SELL	$4.7 - $12.06 $117,053 - $300,354	-24,905 Reduced 13.37%	161,358 $759,000
Q2 2020 Aug 14, 2020	BUY	$5.18 - $14.81 $849,654 - $2.43 Million	164,026 Added 737.63%	186,263 $2.17 Million
Q1 2020 May 14, 2020	BUY	$3.5 - $13.77 $350 - $1,377	100 Added 0.45%	22,237 $128,000
Q4 2019 Feb 14, 2020	BUY	$6.21 - $14.02 $39,396 - $88,942	6,344 Added 40.17%	22,137 $302,000
Q1 2019 May 13, 2019	BUY	$3.35 - $8.27 $1,551 - $3,829	463 Added 3.02%	15,793 $111,000
Q4 2018 Feb 12, 2019	BUY	$3.23 - $8.7 $49,515 - $133,371	15,330 New	15,330 $54,000

Others Institutions Holding ARAV

# of Institutions

Shares Held

28.1K

Call Options Held

Put Options Held

View Full List

About Aravive, Inc.

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

More about ARAV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account